Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Active, Not Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032

Conditions
High-Risk Non-Muscle Invasive Bladder Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083) Anchorage, Alaska, United States
  • Mayo Clinic in Arizona - Phoenix ( Site 1094) Phoenix, Arizona, United States
  • Del Sol Research Management, LLC ( Site 1096) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 1052) Los Angeles, California, United States
View all 209 locations
View Trial Details
Active, Not Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

NCT06049212

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Aichi Cancer Center ( Site 0006) Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East ( Site 0002) Kashiwa, Chiba, Japan
  • National Hospital Organization Shikoku Cancer Center ( Site 0008) Matsuyama, Ehime, Japan
  • Kanagawa Cancer Center ( Site 0004) Yokohama, Kanagawa, Japan
View Trial Details
Active, Not Recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +20 more
Locations
  • HonorHealth ( Site 0041) Phoenix, Arizona, United States
  • Marin Cancer Care ( Site 0055) Greenbrae, California, United States
  • Pacific Cancer Care ( Site 0028) Monterey, California, United States
  • Eisenhower Medical Center ( Site 0067) Rancho Mirage, California, United States
View all 187 locations
View Trial Details
Active, Not Recruiting

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334

Conditions
Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
Locations
  • University of California San Francisco HDFCCC ( Site 4044) San Francisco, California, United States
  • University of Chicago Medical Center ( Site 4037) Chicago, Illinois, United States
  • Indiana University Melvin and Bren Simon Cancer Center ( Site 4011) Indianapolis, Indiana, United States
  • Dana-Farber Cancer Institute ( Site 4047) Boston, Massachusetts, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

NCT06041802

Conditions
Carcinoma, Carcinoma, Squamous Cell, Neoplasms, +5 more
Locations
  • Nagoya University Hospital ( Site 0003) Nagoya, Aichi-ken, Japan
  • Sapporo Medical University Hospital ( Site 0002) Sapporo, Hokkaido, Japan
  • Yokohama City University Hospital ( Site 0016) Yokohama, Kanagawa, Japan
  • Tohoku University Hospital ( Site 0019) Sendai, Miyagi, Japan
View all 18 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394

Conditions
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Parkinson Disease 4, Autosomal Dominant Lewy Body, +2 more
Locations
  • University of Iowa-Holden Comprehensive Cancer Center ( Site 0115) Iowa City, Iowa, United States
  • University of Iowa - Waukee ( Site 0111) Waukee, Iowa, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0114) Las Vegas, Nevada, United States
  • Clinical Research Alliance ( Site 0101) Westbury, New York, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104) Los Angeles, California, United States
  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102) Orlando, Florida, United States
  • University of Chicago Medical Center ( Site 0109) Chicago, Illinois, United States
  • University of Iowa ( Site 0110) Iowa City, Iowa, United States
View all 74 locations
View Trial Details
Active, Not Recruiting

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

NCT06460961

Conditions
Neoplasm Metastasis, Neoplasms, Neoplastic Processes, +3 more
Locations
  • Atlantic Health System Morristown Medical Center ( Site 4001) Morristown, New Jersey, United States
  • Providence Portland Medical Center ( Site 4002) Portland, Oregon, United States
  • South Texas Accelerated Research Therapeutics (START) ( Site 4003) San Antonio, Texas, United States
  • Westmead Hospital ( Site 1002) Westmead, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Infirmary Cancer Care ( Site 0418) Mobile, Alabama, United States
  • Profound Research LLC ( Site 0444) Oceanside, California, United States
  • Clermont Oncology Center ( Site 0421) Clermont, Florida, United States
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0417) Miami, Florida, United States
View all 180 locations
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details

Related conditions